VMS+ 3D Echo and MRI Software
Workstation software for creating 3D heart models from commercial 3D echo or MRI images
Software · On PremiseCompany source
Company profile
About Ventripoint Diagnostics
Ventripoint Diagnostics is a medical technology company specializing in AI-powered cardiac imaging solutions that revolutionize heart diagnostics. The company's flagship product, VMS+, uses proprietary Knowledge Based Reconstruction (KBR) technology to transform standard 2D echocardiograms into high-fidelity 3D models of all four chambers of the heart, delivering volumetric measurements and ejection fractions with accuracy comparable to cardiac MRI at a fraction of the cost and time. The VMS+ system addresses a critical need in cardiac care by providing point-of-care diagnostic capabilities without requiring expensive MRI equipment or perfect imaging conditions. The technology works with any commercially available 2D ultrasound system and features an innovative sensor tracking system that attaches to ultrasound probes, enabling patient repositioning during examinations without affecting results. Analysis takes just minutes, with a simple three-step workflow requiring minimal training. Ventripoint serves major hospitals across Europe, the UK, the US, and Canada, supporting cardiac care for both adult and pediatric patients across all heart conditions including complex congenital malformations. The company's software can be installed on any personal workstation and integrates seamlessly with existing hospital IT infrastructure and PACS systems. By making MRI-level cardiac diagnostics accessible and affordable, Ventripoint is establishing new standards in cardiac imaging and enabling earlier diagnosis and treatment decisions to improve patient outcomes globally.
Company description Ventripoint Diagnostics official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Ventripoint Diagnostics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- All heart conditions in adults and children
- Complex congenital malformations
- Congenital heart disease
- General cardiac function assessment
Who it serves
- Cardiac care centers
- Echo labs
- Hospitals
- Pediatric cardiology departments
Deployment & integration
On Premise deployment with recorded integration context.
Recorded integration context: 3D echo systems, Any commercially available 2D ultrasound system, MRI systems, PACS.
Geographic context
MarketsCanada · Europe · United Kingdom · United States
Company sourceOfficial website
Company milestones
Platform expansion
VMS+ 4.0 release, expansion to major hospitals across Europe, UK, US and Canada, featured by British Heart Foundation and ITV Global Report
Partnerships
Recorded partners
- ASCEND
- British Heart Foundation
- German Heart Center Berlin (DHZC)
- Ollie Hinkle Heart Foundation
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
VMS+ 4.0
AI-powered cardiac imaging that transforms 2D echocardiograms into accurate 3D heart models
Software · On PremiseCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Ventripoint Medical System Plus (VMS+) 4.0K241222 · 510k · Feb 26, 2025
Ventripoint Medical System Plus (VMS+) 3.0K191493 · 510k · Oct 16, 2019
Ventripoint Medical System Plus (VMS+)K173810 · 510k · May 14, 2018
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Accuracy comparable to cardiac MRI
Volumetric measurements and ejection fractions for all four heart chambers
Analysis completed in minutes
Rapid point-of-care diagnostics vs traditional MRI
Fraction of MRI cost and time
Cost-effective alternative to cardiac MRI
Works with low-quality images
Does not require perfect imaging conditions
ASCEND
Providing reliable and effective cardiac imaging tools for clinicians on a global scale
Increased functionality compared to older Ventripoint system, described as 'great addition to echo lab'
DHZC (Deutsches Herzzentrum der Charité)
Precise spatial visualization of complex congenital heart malformations and cardiac function assessment
Enables more precise therapy planning, real-time monitoring, and treatment adjustments for congenital heart disease patients
Ollie Hinkle Heart Foundation
Implementing VMS+ as standard of care across hospital partners
Planning to make VMS+ a standard of care across all hospital partners
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from Ventripoint Diagnostics
Recent articles published on Ventripoint Diagnostics's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.